| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgement
|
|
|
|
33 |
S5 |
p. viii
|
article
|
| 2 |
Editorial Board
|
|
|
|
33 |
S5 |
p. i
|
article
|
| 3 |
ESMO
|
|
|
|
33 |
S5 |
p. vi
|
article
|
| 4 |
Executive Board
|
|
|
|
33 |
S5 |
p. vii
|
article
|
| 5 |
27MO Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer
|
Ghisoni, E.
|
|
|
33 |
S5 |
p. S395
|
article
|
| 6 |
21MO Limited benefit of molecular profiling in patients with low-grade endometrial cancer
|
Vrede, S.
|
|
|
33 |
S5 |
p. S392
|
article
|
| 7 |
28MO Real-world whole sequencing data of ovarian cancer patients
|
Funingana, I.G.
|
|
|
33 |
S5 |
p. S395
|
article
|
| 8 |
20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
|
Lorusso, D.
|
|
|
33 |
S5 |
p. S391-S392
|
article
|
| 9 |
Notice and Disclaimer
|
|
|
|
33 |
S5 |
p. iii
|
article
|
| 10 |
22P A comparison of new ESGO-ESTRO-ESP endometrial risk classification with previous classification in predicting outcome
|
Prakasan, A.M.
|
|
|
33 |
S5 |
p. S392-S393
|
article
|
| 11 |
12P Any size of lymph node metastasis should be considered N1 in patients with cervical cancer
|
Cibula, D.
|
|
|
33 |
S5 |
p. S387
|
article
|
| 12 |
14P A prospective study of comparision of two HDR brachytherapy regimens in treatment of cervical cancer
|
Krishna, A.
|
|
|
33 |
S5 |
p. S388
|
article
|
| 13 |
9P A prospective study of gefitinib in patients with recurrent or metastatic cervical cancer
|
Krishna, A.
|
|
|
33 |
S5 |
p. S386
|
article
|
| 14 |
32P BRCA1/2 mutations in epithelial ovarian cancer: Treatment response and survival analysis in a Spanish tertiary University Hospital
|
Miras Rodriguez, I.
|
|
|
33 |
S5 |
p. S396
|
article
|
| 15 |
48P Clinical profile and treatment outcomes of malignant mixed mullerian tumour of the uterus
|
Vijayaraghavan, N.
|
|
|
33 |
S5 |
p. S402
|
article
|
| 16 |
1P Comprehensive assessment of gene mutations revealed overlapping responses for PARPi and chemotherapy in ovarian cancer cells
|
Tozzi, A.
|
|
|
33 |
S5 |
p. S383
|
article
|
| 17 |
41P Comprehensive genomic profiling in the management of ovarian cancer: National results from Croatia
|
Čerina, D.
|
|
|
33 |
S5 |
p. S399
|
article
|
| 18 |
17P Correlation between human papillomavirus clearance and complete response among Mexican patients with locally advanced cervical cancer treated with chemoradiotherapy
|
Noriega Iriondo, M.F.
|
|
|
33 |
S5 |
p. S389
|
article
|
| 19 |
50P Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: Results of a survey among Italian oncologists belonging to MITO group and AIOM society
|
Tuninetti, V.
|
|
|
33 |
S5 |
p. S403
|
article
|
| 20 |
13P Dosimetric comparisons of brachytherapy applicators used in carcinoma cervix and their utility in toxicity prediction
|
Gokulanathan, N.
|
|
|
33 |
S5 |
p. S387-S388
|
article
|
| 21 |
40P Exome sequencing analysis of primary and recurrent ovarian carcinomas
|
Imyanitov, E.
|
|
|
33 |
S5 |
p. S399
|
article
|
| 22 |
36P Factors associated with platinum resistance in ovarian cancer patients receiving neoadjuvant chemotherapy
|
Gao, Q.
|
|
|
33 |
S5 |
p. S398
|
article
|
| 23 |
5P HOX gene dysregulation in endometrioid ovarian cancer
|
Idaikkadar, P.
|
|
|
33 |
S5 |
p. S384
|
article
|
| 24 |
3P Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
|
Stewart, J.R.
|
|
|
33 |
S5 |
p. S383-S384
|
article
|
| 25 |
34P Immunocytochemical determination of EpCAM protein expression in ascitic fluid cells in the diagnosis of ovarian cancer using the SER1 test system
|
Kruglova, I.A.
|
|
|
33 |
S5 |
p. S397
|
article
|
| 26 |
49P Impact of nutritional factors in response and survival of patients with gestational trophoblastic neoplasia
|
Roque Perez, K.
|
|
|
33 |
S5 |
p. S403
|
article
|
| 27 |
38P Impact of 1-year COVID-19 pandemic in patients with ovarian carcinoma treated with chemotherapy based on a global data network
|
Manso Sanchez, L.M.
|
|
|
33 |
S5 |
p. S398
|
article
|
| 28 |
7P Improving cervical cancer screening in rural India over a 5-year period by training paramedical staff to use visual inspection with acetic acid and thermal ablation: A comparison of cervical cancer rates between villages with and without training
|
Menakuru, S.R.
|
|
|
33 |
S5 |
p. S386
|
article
|
| 29 |
39P Longitudinal increases in albumin-adjusted serum calcium predict ovarian cancer
|
Schwartz, G.
|
|
|
33 |
S5 |
p. S398-S399
|
article
|
| 30 |
43P Malignant bowel obstruction in advanced ovarian cancer: A retrospective analysis of patients supported with parenteral nutrition
|
Wight, R.K.K.
|
|
|
33 |
S5 |
p. S400
|
article
|
| 31 |
30P Molecular biomarkers by next generation sequencing predicting oncological outcomes in ovarian cancer patients
|
Peleg Hasson, S.
|
|
|
33 |
S5 |
p. S396
|
article
|
| 32 |
15P N6-Methyladenosine modification of YY1 mRNA promotes cervical cancer tumorigenesis
|
Arumugam, P.
|
|
|
33 |
S5 |
p. S388
|
article
|
| 33 |
37P Obesity and ovarian cancer: A controversial risk factor
|
Baidoun, F.
|
|
|
33 |
S5 |
p. S398
|
article
|
| 34 |
29P Plasma tumor-derived small extracellular vesicles microRNAs plus CA-125 objectively detect residual disease risk after surgical debulking in advanced ovarian cancer
|
Tang, J.
|
|
|
33 |
S5 |
p. S395-S396
|
article
|
| 35 |
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer
|
Golia D'Auge, T.
|
|
|
33 |
S5 |
p. S387
|
article
|
| 36 |
47P Quality of life after extended pelvic exenterations
|
Cibula, D.
|
|
|
33 |
S5 |
p. S402
|
article
|
| 37 |
35P Racial disparities in diagnosis, histological type, treatment and survival in ovarian cancer patients in the US from 1992 to 2018: SEER-based analysis
|
Zin Eldin, E.I.
|
|
|
33 |
S5 |
p. S397
|
article
|
| 38 |
42P Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor (iPARP), in patients over 65 years of age with ovarian cancer: A current need
|
Martinez Cutillas, M.
|
|
|
33 |
S5 |
p. S399-S400
|
article
|
| 39 |
24P Somatic tumor testing informs on mismatch repair deficiency (MMR-D) phenotype in patients with endometrial cancer
|
Salib, M.
|
|
|
33 |
S5 |
p. S393
|
article
|
| 40 |
2P Spectrum of BRCA1, BRCA1, ATM and PALB2 alleles in ovarian cancer patients from North Caucasus
|
Imyanitov, E.
|
|
|
33 |
S5 |
p. S383
|
article
|
| 41 |
31P Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors
|
Musacchio, L.
|
|
|
33 |
S5 |
p. S396
|
article
|
| 42 |
23P Systematic literature review of real-world outcomes of chemotherapies for advanced or recurrent endometrial cancer
|
Kadambi, A.
|
|
|
33 |
S5 |
p. S393
|
article
|
| 43 |
4P Targeting PI3K/AKT/mTOR pathway in platinum-resistant ovarian high-grade serous carcinoma: Translational analysis from the randomized phase II OCTOPUS trial
|
Giannone, G.
|
|
|
33 |
S5 |
p. S384
|
article
|
| 44 |
33P The development of infrastructure for mainstream ovarian cancer genetic testing (DEMO)
|
Funingana, I.G.
|
|
|
33 |
S5 |
p. S397
|
article
|
| 45 |
25P The impact of COVID-19 on delaying diagnostic-therapeutic pathways of endometrial cancer patients: The Italian real-world scenario
|
Di Donato, V.
|
|
|
33 |
S5 |
p. S393-S394
|
article
|
| 46 |
18P The role of BYL719 in PIK3CA-mutated cervical cancer
|
Bogani, G.
|
|
|
33 |
S5 |
p. S389
|
article
|
| 47 |
16P The role of IL-8 gene polymorphism (845 T/C) in the development of cervical intraepithelial neoplasia
|
Abakumova, T.
|
|
|
33 |
S5 |
p. S388
|
article
|
| 48 |
6P Urine spectroscopy coupled with artificial intelligence: Proof of concept for a new diagnostic tool to detect gynaecological cancers
|
Vigo, F.
|
|
|
33 |
S5 |
p. S384-S385
|
article
|
| 49 |
26P Uterine sarcoma: A retrospective Tunisian study of 103 cases
|
Ouertani, E.
|
|
|
33 |
S5 |
p. S394
|
article
|
| 50 |
8P 20 years of cervical cancer screening program and the impact on hospitalization rates in the public health system in a state of Brazil
|
Silva, A.M.F.
|
|
|
33 |
S5 |
p. S386
|
article
|
| 51 |
10P 10-year survival outcome and patterns of failure analysis of patients with localized adenocarcinoma cervix: Our experience from a tertiary cancer care center
|
Simson, D.K.
|
|
|
33 |
S5 |
p. S386-S387
|
article
|
| 52 |
Table of Contents
|
|
|
|
33 |
S5 |
p. v
|
article
|
| 53 |
45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer
|
Scambia, G.
|
|
|
33 |
S5 |
p. S401
|
article
|
| 54 |
44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
|
Colombo, N.
|
|
|
33 |
S5 |
p. S400-S401
|
article
|
| 55 |
19TiP SGNTUC-019 phase II basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: Uterine and cervical cancer cohorts
|
O'Malley, D.
|
|
|
33 |
S5 |
p. S389-S390
|
article
|
| 56 |
Title Page
|
|
|
|
33 |
S5 |
p. iv
|
article
|
Journal description